ID   Ma-Mel-36
AC   CVCL_A171
SY   Ma-Mel_36; Ma-Mel 36; MaMel-36; MaMel36
DR   cancercelllines; CVCL_A171
DR   Cosmic; 1467752
DR   Cosmic; 1846616
DR   Cosmic; 2686398
DR   ESTDAB; ESTDAB-144
DR   GEO; GSM109062
DR   GEO; GSM437003
DR   GEO; GSM2545599
DR   GEO; GSM2545600
DR   GEO; GSM2545601
DR   IGRhCellID; MaMel36new
DR   Progenetix; CVCL_A171
DR   Wikidata; Q54903789
RX   PubMed=16827748;
RX   PubMed=17311103;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=26909863;
RX   PubMed=28561041;
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503).
CC   Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Tyr281Ter (c.843C>A); Zygosity=Heterozygous (PubMed=28561041).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Cutaneous; UBERON=UBERON_0000014.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A1GP ! Ma-Mel-36-EBV
SX   Female
AG   27Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//
RX   PubMed=28561041; DOI=10.1038/ncomms15440; PMCID=PMC5460020;
RA   Sucker A., Zhao F., Pieper N., Heeke C., Maltaner R., Stadtler N.,
RA   Real B., Bielefeld N., Howe S., Weide B., Gutzmer R., Utikal J.S.,
RA   Loquai C., Gogas H., Klein-Hitpass L., Zeschnigk M., Westendorf A.M.,
RA   Trilling M., Horn S., Schilling B., Schadendorf D., Griewank K.G.,
RA   Paschen A.;
RT   "Acquired IFNgamma resistance impairs anti-tumor immunity and gives
RT   rise to T-cell-resistant melanoma lesions.";
RL   Nat. Commun. 8:15440.1-15440.15(2017).
//